NCT07143877Not yet recruiting
Prognostic Impacts of Lipid Profile and BMI in Adult AML
Prognostic Impacts of Lipid Profile and Body Mass Index in Adult Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy
Source: ClinicalTrials.gov · Last updated 27 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to evaluate the changes in lipid profile parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) in adult AML patients before and after intensive induction chemotherapy. The main questions it aims to answer are: * Are there correlations between metabolic changes (in lipid profile and BMI) and treatment outcomes, including remission status and incidence of chemotherapy-related complications? * Can the baseline lipid profile and BMI serve as prognostic markers for response to induction chemotherapy.? Participants will be observed before and after induction chemotherapy regarding their lipid profile, and BMI, observing any correlations between the different results with any complications, and with remission status.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 15 Aug 2025
- Start date
- 15 Nov 2025
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07143877
What you commit to
- Study type: Observational
- Planned participants: 200
- From 15 Nov 2025 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently using lipid-lowering medications (e.g., statins).
Other illness
- Patients with known endocrine or metabolic disorders affecting BMI or lipid profile (e.g., uncontrolled diabetes, hypothyroidism, Cushing's syndrome).
Other
- Patients with secondary or relapsed AML.
- Pregnant or lactating women.
- Patients unwilling or unable to complete the study protocol.
- Patients with M3 subtype of AML.
Who the study is looking for
- Adult patients (≥18yearsold) newly diagnosed with AML.
- Patients eligible for intensive induction chemotherapy.
- Patients who have given informed consent to participate in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut university Hospitals Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.